Hubro Therapeutics AS raised NOK 7.15 million

Hubro Therapeutics AS, an Oslo, Norway-based company that develops immunotherapies for treatment of cancer, announced the completion of a capital raise totalling NOK 7.15M ($830k).

The funding was provided by a investors from Norway, including Investinor together with Investinor matching partner Radforsk as part of Investinor’s early stage programme. Local business angels are also taking part of the round. The amount will finance Hubro’s pre-clinical programme.

Hubro Therapeutics, founded in 2019 by CEO Jon Amund Eriksen, was built on previous research collaboration between Norsk Hydro and Radiumshospitalet. Following Targovax and Ultimovacs, Hubro will be the 3rd company to initiate trials based on findings from this research project.